Welcome to our dedicated page for Anebulo Pharmaceuticals SEC filings (Ticker: ANEB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the next clinical milestone or spotting insider sales before a data read-out shouldn’t mean combing through 200-page biotech disclosures. Anebulo Pharmaceuticals’ SEC filings are packed with trial data for ANEB-001, FDA pathway updates and cash-runway details—information critical to any investor tracking substance-abuse therapeutics but notoriously hard to parse.
Stock Titan solves that problem. Our AI engine turns dense documents into concise insights so you can move from question to answer in moments. Whether you need Anebulo Pharmaceuticals insider trading Form 4 transactions or an Anebulo Pharmaceuticals quarterly earnings report 10-Q filing, every submission hits our platform in real time, complete with plain-English summaries and key-metric callouts.
- Form 4 alerts showcase Anebulo Pharmaceuticals executive stock transactions Form 4 minutes after they post.
- 10-Q dashboards surface R&D spend trends, giving you an Anebulo Pharmaceuticals earnings report filing analysis without spreadsheets.
- 10-K drill-downs offer an Anebulo Pharmaceuticals annual report 10-K simplified view of clinical risks, patent life and liquidity.
- 8-K flash notes provide Anebulo Pharmaceuticals 8-K material events explained the same day management files them.
- Proxy tools clarify Anebulo Pharmaceuticals proxy statement executive compensation so you can benchmark pay against biotech peers.
Use our “understanding Anebulo Pharmaceuticals SEC documents with AI” feature to compare trial-stage progress quarter over quarter, track Anebulo Pharmaceuticals Form 4 insider transactions real-time, and spot red-flags before the market reacts. Complex biotech filings, finally clear.
On 22 Jul 2025 Opus Genetics (Nasdaq: IRD) executed a Funding & License Agreement with Eyes on the Future and RDH12 Fund for Sight to advance its RDH12 gene-therapy program for inherited retinal degeneration. The Funding Parties will supply up to $1.6 million in milestone-driven, non-dilutive capital that must be used under a mutually agreed development plan.
Opus must meet specific development milestones; failure to do so or other License Trigger Events would give the Funding Parties a non-exclusive, worldwide, royalty-free license to the program. Opus would gain reciprocal access to the generated data and may negotiate for exclusivity, but it cannot grant a third party an exclusive U.S. license during the term without Funding Party consent.
The agreement ends upon (i) dosing three patients in a Phase 1a/2b trial before a trigger event, or (ii) first commercial sale after regulatory approval, and includes standard termination for breach or bankruptcy. The deal is disclosed under Item 1.01; a related press release is furnished as Exhibit 99.1.
FAQ
What is the current stock price of Anebulo Pharmaceuticals (ANEB)?
What is the market cap of Anebulo Pharmaceuticals (ANEB)?
What is the primary focus of Anebulo Pharmaceuticals Inc?
What stage of development is the company currently in?
How does ANEB-001 work to alleviate cannabinoid overdose?
What challenges does a clinical-stage biotech company like Anebulo Pharmaceuticals face?
How does Anebulo Pharmaceuticals differentiate itself within the biotech sector?
What are some key terms associated with Anebulo Pharmaceuticals’ operations?
Who might benefit from the advancements of Anebulo Pharmaceuticals?
How does the company ensure the reliability of its therapeutic candidates?
